AXT is tyrosine kinase inhibitor (TKI), use to treat a variety of cancers such as renal cell carcinoma . It also has anti-angiogenic effect . The aqueous solubility of AXT was determined in-house to be 0.005 g/L (Table ). The compatibility estimation by Ra showed that all the 4 hydrophobic blocks and, surprisingly, the hydrophilic block has similar compatibility (Figure ). To the best of our knowledge, no POx/POzi based AXT formulations are reported so far. At the AXT feed of 2 g/L, all the four triblock copolymer yielded in similar apparent AXT solubility, i.e. ≈ 0.2 g/L (LC ≈ 2 wt.% and LE ≈ 10%). With the increasing AXT feed, the differences in solubilizing capacity for triblock became apparent, especially between A-pBuOx-A and A-pPentOx-A. Like for many other drugs, A-pBuOx-A was found to be the best solubilizer and the maximum achievable solubility was around 1 g/L at 4 g/L AXT feed (LC ≈ 7